Zhimeng Biotechnology is a Chinese biopharmaceutical company focused on developing innovative small molecule therapeutics targeting the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) and related innate immune pathways. Based in Shanghai, the company leverages China's growing expertise in drug discovery and global partnerships to advance its pipeline of NLRP3 inhibitors for neurodegenerative and inflammatory diseases.
Company Profile
| Attribute | Value | |-----------|-------| | Founded | 2018 | | Headquarters | Shanghai, China | | CEO | Dr. Wei Zhang | | Funding | Series B ($40M, 2023) | | Focus | NLRP3 inhibitors, innate immunity | | Stage | Preclinical/IND-enabling |
Business Model
Zhimeng operates with a hybrid model:
Internal discovery: Proprietary small molecule library and screening platform
Academic partnerships: Collaborations with Chinese universities and research institutes
Global licensing: Out-licensing of programs to global partners for major markets
Science and Technology
NLRP3 Platform
Zhimeng's NLRP3 program is built on:
High-throughput screening: Automated screening of compound libraries
Structure-activity relationship (SAR): Rapid optimization of lead compounds
In vivo pharmacology: Robust PD models including MPTP and 6-OHDA
Approach
The company focuses on developing next-generation NLRP3 inhibitors with:
...
Overview
Zhimeng Biotechnology is a Chinese biopharmaceutical company focused on developing innovative small molecule therapeutics targeting the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) and related innate immune pathways. Based in Shanghai, the company leverages China's growing expertise in drug discovery and global partnerships to advance its pipeline of NLRP3 inhibitors for neurodegenerative and inflammatory diseases.
Company Profile
| Attribute | Value | |-----------|-------| | Founded | 2018 | | Headquarters | Shanghai, China | | CEO | Dr. Wei Zhang | | Funding | Series B ($40M, 2023) | | Focus | NLRP3 inhibitors, innate immunity | | Stage | Preclinical/IND-enabling |
Business Model
Zhimeng operates with a hybrid model:
Internal discovery: Proprietary small molecule library and screening platform
Academic partnerships: Collaborations with Chinese universities and research institutes
Global licensing: Out-licensing of programs to global partners for major markets
Science and Technology
NLRP3 Platform
Zhimeng's NLRP3 program is built on:
High-throughput screening: Automated screening of compound libraries
Structure-activity relationship (SAR): Rapid optimization of lead compounds
In vivo pharmacology: Robust PD models including MPTP and 6-OHDA
Approach
The company focuses on developing next-generation NLRP3 inhibitors with:
Enhanced BBB penetration: Optimized for CNS indications
Improved pharmacokinetics: Once-daily oral dosing
Reduced off-target effects: High selectivity for NLRP3